Company Pasithea Therapeutics Corp.

Equities

KTTA

US70261F2020

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 03:59:57 2024-05-06 pm EDT			5-day change	1st Jan Change
7.13 ^USD	+3.03%		+3.03%	-3.65%

Apr. 24	Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers	CI
Mar. 29	Pasithea Therapeutics Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.

Number of employees: 8

Managers	Title	Age	Since
Tiago Marques CEO	Chief Executive Officer	47	20-07-31
Daniel Schneiderman DFI	Director of Finance/CFO	46	22-06-30
Graeme Currie PRN	Corporate Officer/Principal	57	22-05-31

Members of the board	Title	Age	Since
Lawrence Steinman FOU	Founder	76	19-12-31
Alfred Novak BRD	Director/Board Member	76	22-09-13
Emer Leahy BRD	Director/Board Member	58	21-05-31
Tiago Marques CEO	Chief Executive Officer	47	20-07-31
Simon Dumesnil BRD	Director/Board Member	47	21-03-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,042,415	1,031,413 ( 98.94 %)	0	98.94 %

Name	Equities	%	Valuation
Paul Manning 12.52 %	130,434	12.52 %	945 647 $
Lawrence Steinman 6.369 %	66,358	6.369 %	481 096 $
Uday R Khire 5.894 %	61,405	5.894 %	445 186 $
Tiago Marques 3.647 %	37,999	3.647 %	275 493 $
Geode Capital Management LLC 0.6005 %	6,256	0.6005 %	45 356 $
Simon Dumesnil 0.2400 %	2,500	0.2400 %	18 125 $
Northern Trust Investments, Inc.(Investment Management) 0.2259 %	2,354	0.2259 %	17 067 $
Renaissance Technologies LLC 0.1560 %	1,625	0.1560 %	11 781 $
Jane Street Group LLC 0.1132 %	1,179	0.1132 %	8 548 $
Tower Research Capital LLC 0.0595 %	620	0.0595 %	4 495 $

Name	Equities	%	Valuation
Armistice Capital LLC -	1,000,000	-	12 000 $
Kepos Capital LP -	334,600	-	4 015 $
Warberg Asset Management LLC -	289,868	-	3 478 $
Citadel Securities GP LLC -	13,104	-	157 $

Pasithea Therapeutics Corp.

1111 Lincoln Road Suite 500

33139, Miami Beach

http://www.pasithea.com

address Pasithea Therapeutics Corp.(KTTA)

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
PASITHEA THERAPEUTICS CORP.	-3.65%	7.21M
REGENERON PHARMACEUTICALS, INC.	+9.22%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-1.08%	104B
ARGENX SE	+5.79%	22.94B
BIONTECH SE	-11.47%	22.34B
GENMAB A/S	-7.01%	19.25B
WUXI APPTEC CO., LTD.	-37.08%	17.08B
BEIGENE, LTD.	-9.95%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+7.58%	14.16B
SAREPTA THERAPEUTICS, INC.	+40.03%	12.63B

Bio Therapeutic Drugs